YEAR-END REPORT 1 JANUARY – 31 DECEMBER 2023
· Continued stable growth despite restructuring of commercial organization, and satisfactory start in the US with significant opportunities ahead · Restructuring program completed with planned cost reduction expected 2024 · 510(k)-process ongoing with US FDA for big toe implant“Despite significantly restructuring our sales force, we ended the year with another record quarter. On average, we have grown our gross order intake by more than 50% during the last five quarters. During 2023, the gross order intake reached SEK 11.1m (+56%). The usage of our technology increased globally and